Safety, efficacy, and dosing comparison of once-daily OROS hydromorphone and immediate-release hydromorphone in patients with chronic non-cancer pain

被引：0
|
作者：
Bornhovd, K.
Richarz, U.
Berliner, M. N.
Thipphawong, J.
机构：
[1] Janssen Cilag Germany, Med & Sci Affairs, Neuss, Germany
[2] Janssen Cilag Europe, Med Affairs, Baar, Switzerland
[3] Univ Klinikum Gieben, Med Klin & Poliklin 3, Rodthohl, Germany
[4] ALZA Corp, Med Res, Mountain View, CA USA
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2006年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：562 / 562
页数：1
相关论文
共 50 条
  • [1] COMPARATIVE CLINICAL EFFICACY AND SAFETY OF IMMEDIATE-RELEASE AND CONTROLLED-RELEASE HYDROMORPHONE FOR CHRONIC SEVERE CANCER PAIN
    HAYS, H
    HAGEN, N
    THIRLWELL, M
    DHALIWAL, H
    BABUL, N
    HARSANYI, Z
    DARKE, AC
    CANCER, 1994, 74 (06) : 1808 - 1816
  • [2] Impact of once-daily oros hydromorphone on the sleep profile of patients with severe chronic low back pain
    Dubois, D.
    Wallace, M. S.
    Richarz, U.
    Kosinski, M.
    Thipphawong, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 238 - 239
  • [3] Sustained Safety and Efficacy of Once-Daily Hydromorphone Extended-Release (OROS® hydromorphone ER) Compared with Twice-Daily Oxycodone Controlled-Release Over 52 Weeks in Patients with Moderate to Severe Chronic Noncancer Pain
    Richarz, Ute
    Waechter, Sandra
    Sabatowski, Rainer
    Szczepanski, Leszek
    Binsfeld, Heinrich
    PAIN PRACTICE, 2013, 13 (01) : 30 - 40
  • [4] Long-Term Efficacy of OROS® Hydromorphone Combined with Pregabalin for Chronic Non-Cancer Neuropathic Pain
    Mario Dauri
    Marzia Lazzari
    Manuela Casali
    Giuseppe Tufaro
    Elisabetta Sabato
    Alessandro Fabrizio Sabato
    Clinical Drug Investigation, 2014, 34 : 309 - 316
  • [5] Long-Term Efficacy of OROS® Hydromorphone Combined with Pregabalin for Chronic Non-Cancer Neuropathic Pain
    Dauri, Mario
    Lazzari, Marzia
    Casali, Manuela
    Tufaro, Giuseppe
    Sabato, Elisabetta
    Sabato, Alessandro Fabrizio
    CLINICAL DRUG INVESTIGATION, 2014, 34 (05) : 309 - 316
  • [6] Once-daily OROS® hydromorphone for the management of chronic nonmalignant pain:: a dose-conversion and titration study
    Wallace, M.
    Rauck, R. L.
    Moulin, D.
    Thipphawong, J.
    Khanna, S.
    Tudor, I. C.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2007, 61 (10) : 1671 - 1676
  • [7] Effect of once-daily oros hydromorphone and sustained-release oxycodone on pain, disability, and joint stiffness associated with chronic osteoarthritis pain
    Waechter, S.
    Richarz, U.
    Roth, S.
    Thipphawong, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 410 - 410
  • [8] Once-daily OROS hydromorphone ER compared with placebo in opioid-tolerant patients with chronic low back pain
    Hale, M.
    Khan, A.
    Kutch, M.
    Li, S.
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (06) : 1505 - 1518
  • [9] Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127)
    Wallace, Mark
    Skowronski, Roman
    Khanna, Sarita
    Tudor, Lulia Cristina
    Thipphawong, John
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (05) : 981 - 989
  • [10] EUROPEAN ECONOMIC EVALUATION OF OROS® HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN
    Hauber, A. B.
    Lam, A.
    Fleischmann, J.
    Wilson, M. R.
    VALUE IN HEALTH, 2008, 11 (06) : A640 - A640
12345